In malignant tumors, metastasis genes are typically deregulated by aberrant expression or splicing. Osteopontin is expressed at high levels by various cancers and contributes importantly to their invasive potential. In contrast, osteopontin derived from host cells induces cellular immunity and could bolster antitumor protection by cytotoxic T lymphocytes. Here we show that breast cancer cells express multiple splice variants of osteopontin. According to RT-PCR analysis of human breast tissue specimens, the splice variant osteopontin-c is a highly specific marker for transformed cells, which is not expressed in their surrounding normal tissue. The fulllength form of osteopontin aggregates in the presence of physiologic amounts of calcium and, in this state, leads to enhanced cell adhesion. Ostensibly, this effect is inhibitory for tumor cell dissemination. The shortest splice variant, osteopontin-c, does not aggregate in the presence of calcium and enhances clone formation in soft agar. According to microarray analysis, osteopontin-c induces the expression of oxidoreductases, consistent with protection from anoikis during anchorage-independent growth. These studies define a third functional domain of osteopontin, beside the C-terminal CD44-binding site and the central integrin-binding site. They also provide evidence for a bifunctional character of osteopontin, with the soluble form supporting invasiveness and the aggregated form promoting adhesion.
Introduction
The genetic basis of cancer dissemination has been subject to intense debate. We have identified metastasis genes as stress response genes, which in cancer are deregulated on the levels of aberrant expression and splicing (Weber and Ashkar, 2000a, b) . The cytokine osteopontin (OPN) is frequently secreted by cancer cells and plays important roles in their ability to metastasize (Sung et al., 1998; Urquidi et al., 2002; El-Tanani et al., 2001a, b) . Its expression is necessary and may be sufficient for invasiveness by breast tumors (Tuck et al., 1999; Zhang et al., 2003) . Multiple metastatic breast cancer cell lines express osteopontin, and transfection of the osteopontin gene into benign tumorigenic human breast epithelial cell lines conveys invasive behavior (Chen et al., 1997; Barraclough et al., 1998) . Increasing the expression of osteopontin or transfection of osteopontin-encoding cDNA into a previously benign cell line is sufficient to produce a metastatic phenotype in a rat mammary model (Oates et al., 1996) . Furthermore, high levels of osteopontin in the plasma or in the tumor are an adverse prognostic factor in breast carcinoma (Singhal et al., 1997; Rudland et al., 2002) . Osteopontin binds to the metastasisassociated cell surface receptors integrin a V b 3 and CD44v3-6 and mediates cell migration. Osteopontininduced chemotaxis is conveyed through the binding of a C-terminal domain to a CD44 splice variant (Weber et al., 1996) . Cells can also move up a gradient of immobilized ligand. This cell crawling may occur on vessel walls or in the interstitium and is referred to as haptotaxis. Haptotaxis toward osteopontin is mediated through ligation of the integrin a V b 3 by a N-terminal osteopontin domain. Integrin engagement depends not only on the RGD motif, but also on the phosphorylation of specific osteopontin sites (Weber et al., 2002) . Of note, the physiologic or patho-physiologic roles of the far N-terminal osteopontin domains (including exons 4 and 5) have not yet been defined.
The immune system may protect from tumorigenesis. The cellular arm, activating cytotoxic T lymphocytes and natural killer cells as effectors, is considered to be a critical part of this immune surveillance. The cytokine osteopontin is secreted by activated helper T lymphocytes and is essential for the induction of cellular immune responses (Ashkar et al., 2000; O'Regan et al., 2000; Adler et al., 2001) . Osteopontin induces the secretion of IL-12 from macrophages, a cytokine that is effective in activating antitumor immunity (Chen et al., 1996; Zitvogel et al., 1996) . Host osteopontin also acts as a macrophage chemoattractant and thus contributes to the antitumor host defense, whereas tumor osteopontin inhibits macrophage function (Crawford et al., 1998) . The structural basis for the potential of host-derived osteopontin to contribute to suppressing tumor formation, whereas osteopontin secreted by transformed cells enhances their metastatic propensity, has not been elucidated.
Heterogeneity of osteopontin derived from various cellular sources has been described previously, but the underlying biochemical processes are incompletely understood. By Western blotting and in a set of sandwich ELISA setups, characterized by the use of various antibody combinations, tumor-derived osteopontin was differentially detected (Rittling and Feng, 1998; Kon et al., 2000) . Osteopontin forms of distinct sizes, according to SDS-PAGE, are secreted by tumor cells and their nontransformed counterparts. Specifically, cancer cells may secrete a splice variant that has a deletion in its N-terminal portion (Kiefer et al., 1989) . As a case in point, an osteosarcoma secreted a smaller form of osteopontin than the predominant product generated by nontransformed bone cells. The secretion of the smaller form correlated with anchorage independence (Chackalaparampil et al., 1985; Kasugai et al., 1991) . This may reflect a loss of adhesion to osteopontin because, in contrast to host osteopontin, tumor-derived osteopontin fails to associate with the extracellular matrix and remains soluble (Rittling et al., 2002) .
The existence in humans of two osteopontin splice variants with deletions of exon 4 (referred to as osteopontin-c) or 5 (called osteopontin-b) ( Figure 1a ) has been described (Young et al., 1990) and has been observed to be expressed in glioma cells (Saitoh et al., 1995) . Differences in the physiologic roles among these variants have not been studied. Here we test the possibility that splice variants of osteopontin may be expressed selectively in malignant tumors and facilitate their dissemination. The functional alterations associated with the alternatively spliced exons may account for the observed differences between host and tumor osteopontin.
Results
Multiple osteopontin forms are expressed by breast cancer cells We analysed osteopontin gene expression in various breast tumor cells by RT-PCR using primers that span an upstream region covering exons 2-6. To eliminate skewing of the results by activation of the cells through growth factors in the medium, we used serum-free conditions. The malignant breast cancer cell lines MDA-MB-435 and MDA-MB-231 express three distinct RNA messages of osteopontin. MCF-7 cells are noninvasive and do not contain measurable osteopontin RNA levels ( Figure 1b) . The two smaller osteopontin transcript bands selectively expressed in malignant cells were identified by cloning and sequencing as splice variants missing the third or fourth translated exons (exons 4 or 5, because exon 1 is untranslated (Behrend et al., 1993) ). Other invasive cell lines tested, including cancers of diverse tissue origin, express multiple osteopontin messages (Hela, SAOS-2, 21MT1, 21MT2), while all noninvasive cell lines tested (ZR-75-1, 21NT, LnCAP) express no osteopontin or low levels of osteopontin-a without splice variants (data not shown). The identified transcripts correspond to the sequences of 'osteopontina, ' 'osteopontin-b' and 'osteopontin-c,' which are listed in GenBank (Accession numbers D28759, D28760, and D28761) but have not been thoroughly studied. Published reports on the expression or function of the splice variants are limited to the observation of three types of osteopontin RNA messages in human gliomas (Saitoh et al., 1995) and to the existence of a splice variant that has a deletion in its N-terminal portion (Kiefer et al., 1989) . The secretion of multiple osteopontin forms by the invasive breast cancer cell line MDA-MB-435, but not by the noninvasive breast tumors MCF-7 and ZR-75-1 was confirmed by Western blotting (Figure 1c) .
Through the tissue repository at the University of Cincinnati Medical Center, we obtained breast tumor specimens, surrounding nontransformed tissue, and normal breast tissue (derived from reduction mammoplasty). We performed RT-PCR with pairs of primers that are specific for the splice variants osteopontin-a or -c (amplification of GAPDH served as a control for abundance and integrity of the cDNA, amplification without a template confirmed the absence of aerosol contamination). Three of four breast carcinomas expressed high levels of osteopontin-c. For two of them, surrounding tissue was available, one of which expressed low levels of osteopontin-a, but neither expressed detectable levels of osteopontin-c. We also studied five invasive ductal carcinomas. All expressed osteopontin-a and -c messages. While the surrounding tissue, available from three patients, had low amounts of osteopontin-a, none expressed osteopontin-c. The expression levels of osteopontin-a varied in 11 specimens of normal breasts. This may reflect the production of unspliced osteopontin, which is physiologically secreted in milk, by breast cells depending on the stages of the estrous cycle. Osteopontin-c transcripts were never detected in the normal tissue samples (Figure 1d ). These results suggest that osteopontin splicing is specific to tumor cells.
Osteopontin-c facilitates soft agar colony formation more than osteopontin-a We stably transduced full-length osteopontin (variant a) and splice variant c into MCF-7 cells, which do not express endogenous osteopontin (Figure 2a and b) . After incubation of the cells for 14 h in serum-free medium, abundant amounts of osteopontin were secreted into the supernatants of the transfected cells, but not the vector controls. Consistent with previous observations (Tuck et al., 1999) , a second, slower migrating band was observed, possibly reflecting phosphorylation or glycosylation. The smaller band could result from thrombin cleavage of this modified form.
Overexpression of osteopontin was also seen in the cell lysates.
Because we had previously found osteopontin to facilitate clone formation in soft agar (Zhang et al., 2003) , we tested whether the transfection of osteopontin-a or -c changed the phenotype of MCF-7 cells in this assay. In fact, osteopontin-c facilitated soft agar clone formation and the clones formed after 7 days show distinct protrusions, which are absent from osteopontin-a-transfected cells or vector controls and which we believe to be indicative of the rapid expansion of the clones within the agar (Figure 3a and b). These changes were directly dependent on the osteopontin protein because the addition of anti-osteopontin antibody, but not control immunoglobulin, to the cultures every other day with the exchange of medium suppressed the formation of clones by the transfected MCF-7 cells. In contrast, the antibody had no effect on the clones formed by vector-transfected MCF-7 cells (Figure 3c ). The clone sizes of osteopontina-transfected MCF-7 cells were moderately, but statistically significantly larger than the vector control, and osteopontin-c-transfected cells formed significantly larger colonies than osteopontin-a transfectants ( Figure 3d ). Similar results were obtained with additional clones (MCF-7 OPNa1, MCF-7 OPNc16).
Neither osteopontin-c nor -a alters cell cycle progression To account for the changes in soft agar growth characteristics, we first asked whether the growth rates of the osteopontin-expressing MCF-7 transfectants were altered as compared to a vector-transfected MCF-7 clone. Consistent with our earlier results, which had indicated that osteopontin expression affects motility but not cell growth (Zhang et al., 2003) , there were no differences in cell numbers among MCF-7 vector, MCF-7 osteopontin-a, and MCF-7 osteopontin-c over 6 days of analysis ( Figure 4a ). Confirmatory experiments with additional stably transfected clones (MCF-7 v2, MCF-7 OPNa2, and MCF-7 OPNc16) yielded similar results.
Osteopontin-a, but not osteopontin-c supports calcium-dependent cell adhesion As different growth rates did not account for the distinct phenotypes generated by osteopontin-a and -c in soft agar, we set out to analyse MCF-7 cell adhesion as a factor that regulates anchorage independence. We found (Weber et al., 2002) . Binding to b 1 -containing integrins occurs through the noncanonical sequence SVVYGLR (Yokosaki et al., 1999) , unless the b 1 chain is paired with a 4 , in which case the binding site ranges from AA131 to AA144 (Bayless et al., 1998) . We have found the CD44v3-6-binding site to cover the region from AA169 to AA220 (Ashkar et al., 2000 and Ashkar/Weber unpublished results) . Heparin bridges between osteopontin and CD44v3 may be formed via the heparin-binding sites on AA170 and 300. Note that AA1-70 are not known to be involved in receptor ligation, their function has not been defined. The bases of the coding sequence and the corresponding amino acids are numbered such that the start site, or initiating methionine is 1. The scheme is not drawn to scale. (b) The cells were plated at 1 Â 10 5 /well in 24-well plates and allowed to adhere for 7 h before starvation in growth factor-and serum-deprived medium. Total RNA was extracted, reverse transcribed with oligo-dT and PCR was performed with primers that span the region from base pairs 50 to 246 with the primers 5 0 -tac cag tta aac agg ctg att c-3 0 and 5 0 -cca tat cat cca tgt ggt ca-3 0 . PCR of GAPDH was used as a control for the amount of template present. OPN ¼ osteopontin; GAPDH ¼ glyceraldehyde 3-phosphate dehydrogenase. The slowest migrating band (no arrow) seen in MDA-MB-435 cells was often present in the no-template control sample and is deemed to be nonspecific. MCF-7 cells are noninvasive while MDA-MB-435 and MDA-MB-231 are metastatic. (c) Western blotting to detect secreted osteopontin in cell culture supernatant. ZR75-1 is noninvasive. Supernatant from MCF-7 cells transfected with osteopontin-c was loaded as a positive control. The lower panel shows a Western blot at low exposure to demonstrate the separation of three bands in the MDA-MB-435 supernatants. (d) The expression of osteopontin-a and osteopontin-c in human breast tissue specimens was assessed by RT-PCR (with amplification of GAPDH controlling for template integrity and abundance). According to the intensity of the resulting band on agarose gel, the expression levels were rated as high, low, or absent. Indicated are the numbers of specimens identified in each group. The panel to the right shows the RT-PCR results for a representative invasive DCIS (ductal carcinoma in situ) sample (T) and its surrounding normal tissue (N), M ¼ size markers.
Osteopontin splicing in cancer B He et al that GST-OPNa but not GST-OPNc had a tendency to aggregate in the presence of physiologic concentrations of calcium. The same phenomenon occurred with serum-free supernatants from the transfected MCF-7 cells (Figure 4b and c). Chelation with EDTA could prevent this phenomenon and magnesium, another divalent cation, could not substitute for calcium (Figure 4d ). MCF-7 cells adhered to and spread dose dependently on increasing amounts of purified recombinant GST-OPN (Figure 4e and f). When plated with increasing amounts of calcium, the adhesion to GSTOPNa, but not to GST-OPNb or GST-OPNc, became stronger (Figure 4g ).
Osteopontin influences the gene expression profile in soft agar
To further characterize the molecular basis for the enhancement of soft agar colony formation by osteopontin-c (increased clone size after 7 days, see Figure 3 ), we extracted the cellular RNA after 7 days of growth in soft agar and performed microarray analysis comparing MCF-7 OPNc16 to MCF-7 OPNa1 and to MCF-7 v1. In all, 525 genes were significantly differentially expressed between MCF-7 OPNc and MCF-7 vector according to normalized individual array ratios. The groups of genes affected by osteopontin-c (as compared to vector) include oxidoreductases and ion transporters Figure 3 Expression of the osteopontin splice variant-c enhances the colony formation in soft agar more than osteopontin-a. Transfected MCF-7 cells were plated in triplicates with a top layer of 0.3% agar and a bottom layer of 0.5% agar. Every other day, 0.4 ml of medium was supplemented and the plates were examined microscopically for growth. (a) Microscopic pictures were taken on days 1 (top panels) and 7 (bottom panels) after plating at low magnification (to show clone frequency) and at large magnification (to show clone size and shape). Protrusions from the clones formed are visible in MCF-7 OPNc1, but not in the MCF-7 cells transfected with osteopontin-a (MCF-7 OPNa3) or in the vector control (MCF-7 v1). (b) The combined data from three experiments were evaluated to determine the average clone size (relative units) and clone frequency, formed by MCF-7 cells transfected with vector, osteopontin-a, or osteopontin-c. 5 fields per plate were photographed and all clones in focus were measured. The table shows the mean and range of all measured clones (indicated as n). The differences among the groups in clone size, but not in clone frequency, were statistically significant according to the t-test. (c) Soft agar colony formation by transfected MCF-7 cells was evaluated in the absence of antibody (top panel) or with addition every other day of anti-osteopontin antibody at 0.5 mg/ml in 0.3 ml medium (bottom panel) or rabbit IgG (Sigma) as immunoglobulin control (middle panel). (d) The average clone size was quantitated by measuring the area of all focused colonies in five randomly chosen high-powered fields using image analysis software. The data represent mean7s.d. The data sets were analysed for statistically significant differences by the U-test (Wilcoxon, Mann, and Whitney) and the t-test. The clone sizes for MCF-7 OPN-a and MCF-7 OPN-c are statistically significantly different from the clone sizes of MCF-7 vector and from one another. OPN ¼ osteopontin. Figure 5B ). This is not a dosage effect, Osteopontin splicing in cancer B He et al because the amount of osteopontin secreted by MCF-7 OPNa was higher than the amount secreted by MCF-7 OPNc, as judged by Western blotting at the beginning of the soft agar experiment (data not shown).
Discussion
We have found that alternative splicing is one mechanism, by which cancer cells alter the structure and function of osteopontin, leading to increased anchorage independence. The functional implications of splicing of the small exon 4 (27 amino acids), which translates to a domain far N-terminal on the osteopontin protein, has been enigmatic. The multiple receptor binding sites for integrins and variant CD44 have been mapped to downstream regions (Weber et al., 2002) and the role of exon 4 was unknown. Osteopontin can form multimers that may participate in adhesion within mineralized tissue (Goldsmith et al., 2002) and there are functional differences between the soluble and the matrix-associated osteopontin (Adler et al., 2001; Rittling et al., 2002) . As evidenced by the absence of connective tissue defects in the osteopontin knockout mice, the wide expression of the extracellular matrix protein osteopontin may not reflect important structural roles, but rather its availability for rapid release in stress responses, during which osteopontin is needed for immune stimulation and tissue remodeling. We have found that osteopontin-c strongly supports anchorageindependent growth. In contrast, osteopontin-a has an intermediate effect, possibly reflecting an equilibrium, in which a portion of the secreted product aggregates, with the remaining soluble portion supporting soft agar clone formation. Our data imply a paradigm, according to which the soluble form of osteopontin promotes metastasis, but the aggregated form does not. The exons 4 and 5 may play a critical role in osteopontin solubility. Osteopontin has been known to exert strong effects on the redox status of various cells and to prevent programmed cell death in response to diverse stimuli (Hwang et al., 1994; Denhardt et al., 1995; Weber et al., 1999) . The induction of various oxidoreductase genes by osteopontin, found in the microarray analysis, is consistent with these functions. Apoptosis frequently involves the generation of and signal transduction by free radicals (Weber et al., 1995) . Anchorage independence in soft agar largely reflects resistance to a form of apoptosis referred to as anoikis. The induction of oxidoreductase genes by osteopontin may cause its antioxidant and antianoikis effects. These do not come into play during the growth of cells in culture dishes where oxidative stress or loss of anchorage are minimal, but they are prominent in semisolid medium. The role of the osteopontin-dependent upregulation of ion transporter genes in breast cancer remains to be clarified. It should be noted, however, that many of the genes in this group are also categorized as oxidoreductases (see Figure 5a ). Osteopontin-c lacks a domain compared to the standard form of the molecule. This prevents it from aggregating and makes more soluble osteopontin available for receptor ligation. Consistently, most of the differences in gene expression detected by microarray are similar, but more extensive for osteopontin-c versus vector as compared to osteopontin-c versus -a or osteopontin-a versus vector. Of the 525 significantly differently expressed genes in the comparison of osteopontin-c versus vector, all but 20 changed in the same direction (induction or suppression) in the osteopontin-c versus -a hybridizations. Only a small number of genes may be uniquely induced by osteopontin-c. Further studies should clarify whether in addition to the loss of function, reflected in the lack of calcium-dependent aggregation and cell adhesion, osteopontin-c gains new functions, possibly through the ligation of a novel receptor.
It may be important to note that it is not unexpected for tumors to express multiple variant transcripts of metastasis-associated genes. Similar observations have been made for the homing receptor CD44. Tumors may express up to nine distinct spliced forms of this gene (Matsumura and Tarin, 1992) . Only certain CD44 splice variants support metastasis (Gunthert et al., 1991) , while the standard form acts as an inhibitor of dissemination (Tanabe et al., 1995) . By inference, it is possible that full-length osteopontin tends to immobilize cells, while the spliced osteopontin variants may be critical to breast cancer metastasis. This is supported by our observation of aggregation of osteopontin-a, resulting in enhanced cell adhesion, at physiologic calcium concentrations. Exon 4 appears to be necessary for this function, because osteopontin-c remains soluble.
Alternative splicing of osteopontin is not known to occur in mice. By RT-PCR, we have not detected more than one message in various murine tissues (unpublished results). Overexpression of full-length osteopontin has induced invasive behavior in mouse tumor models. There are two possible reasons for this. The unphysiologically high level of overexpression Figure 5 Alterations in gene expression profiles induced by osteopontin-c and -a in soft agar. Cellular RNA was extracted from soft agar after 7 days, and subjected to linear amplification, cDNA synthesis and dye labeling for microarray analysis of MCF-7 OPNc compared to MCF-7 vector, MCF-7 OPNc compared to MCF-7 OPNa, and MCF-7 OPNa compared to vector. (a) Genes significantly altered (probability of error o0.005) by osteopontin-c as compared to vector according to EASE analysis. The Genbank accession numbers in italic are also detected as altered in the EASE analysis of osteopontin-c versus osteopontin-a. Osteopontin splicing in cancer B He et al typically achieved by transfection may generate sufficient levels of nonaggregated osteopontin to facilitate cell migration. Alternatively, the apparent absence of osteopontin splicing in mice, typically used as an in vivo model for dissemination, may render them susceptible to full-length osteopontin. Owing to the restrictions in structural diversity of osteopontin, mouse models may have limitations for investigating osteopontin in cancer.
Materials and methods
Cell lines and reagents MCF-7 cells, were grown in a-MEM with insulin and 10% fetal bovine serum (FBS). MDA-MB-435 cells were obtained from Dr Danny Welch and cultured as described (Seraj et al., 2000) . The metastatic breast cancer cell line MDA-MB-231 (ATCC HTB-26) was grown in a-MEM with 10% FBS. ZR-75-1 (ATCC HTB-22) cells are derived from a ductal carcinoma, are tumorigenic but noninvasive. They were grown in RPMI with 10% FBS. 293T cells were used for transient transfections as previously described . The anti-osteopontin antibody was purchased from Assay Designs Inc. For application in the soft agar assay, a special order aliquot without azide was used.
DNA constructs and transfection
The constructs for expression of the human osteopontin splice variants were obtained by reverse transcription-PCR from the malignant breast tumor cell line MDA-MB-435. Total RNA was isolated by using RNeasy mini kit (Qiagen, Valencia, CA, USA) following the manufacturer's protocol. 1 mg of total RNA was used for cDNA synthesis with Super-script II reverse transcriptase (Gibco BRL, USA). The coding sequence of osteopontin was amplified with the primers 5 0 -CAA ACG CCG ACC AAG GGA AAA C-3 0 and 5 0 -CTT CTT TCT CAG TTT ATT GGT-3 0 . The amplified product was TA cloned, excised with Xho1 and NheI, and was subcloned into the vector pCR3.1 (Invitrogen Carlsbad, CA, USA). Genes cloned into this vector are expressed under the control of the CMV promoter. Sequence fidelity and accurate reading frame were verified by DNA sequencing analysis. MCF-7 cells were transfected by the Fugene method and stable clones were selected in G418.
For the generation of GST-OPN fusion proteins, osteopontin cDNAs were amplified by PCR by exclusion of the signal peptide (1-17 amino acids) with the primers 5 0 -c ggg atc ccc ATA CCA GTT AAA CAG GCT GAT-3 0 and 5 0 -gg ctc gag ATG TTC TCT TTC ATT TTG CTA-3 0 using pCR3.1-OPNs as templates (the lower case letters show BamHI and XhoI sites and protective bases to facilitate cloning). The amplified fragments were subcloned into pGEX-5T vector and transformed into BL21 bacteria for making GST-OPN fusion proteins. Reading frames and sequence fidelity were confirmed by sequencing analysis.
Human breast cancer tissue Specimens of human breast tumors, nontransformed surrounding tissue, as well as healthy breast tissue (obtained from reduction mammoplasties) were provided by the tissue procurement facility of the University of Cincinnati Medical Center.
RT-PCR
Total RNA was extracted from human tissues using Trizol R (1 ml reagent/200 mg tissue), according to the manufacturer's protocol. 3 mg of total RNA was reverse transcribed by SuperScript II reverse Transcriptase (Invitrogen, Carlsbad, CA, USA). The osteopontin splice variants -a and -c were amplified with the primer pairs 5 0 -ATCTCCTAGCCCCACA GAAT-3 0 (forward) and 5 0 -CATCAGACTGGTGAGAATCA TC-3 0 (reverse) for osteopontin-a and 5 0 -CTGAGGAAAAG CAGAATG-3 0 (forward) and 5 0 -AATGGAGTCCTGGCT GT-3 0 (reverse) for osteopontin-c. The amplification of GAPDH with primers 5 0 -TGAAGGTCGGAGTCAACGGA TTTGGT-3 0 (forward) and 5 0 -CATGTGGGCCATGAGGTC CACCAC-3 0 (reverse) served as a control for equal loading and integrity of the cDNA. A 35 cycle touchdown PCR, with Taq DNA Polymerase and at 1.5 mM MgCl 2 , was performed with five cycles at 591C annealing temperature, five cycles at 551C annealing temperature, and 25 cycles at 511C annealing temperature. All PCR products were analysed by Tris-acetate EDTA agarose (2.5% w/v) gel electrophoresis. To confirm the specificity of the primer pairs for osteopontin-a and -c, we cloned and sequenced their PCR products from a representative tumor sample.
Immunoblot assay
For the analysis of secreted osteopontin, serum-free cell culture supernatant was collected from each transfectant. In all, 40 ml of supernatant per sample were electrophoresed on 10% SDS-polyacrylamide mini-gels with nonreducing sample buffer. For the analysis of intracellular osteopontin, the cells were lysed in RIPA buffer (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 1% NP-40, 0.5% Na-deoxycholate, 0.1% sodium dodecyl sulfate). Cell lysates at equal amounts of protein (20 mg/lane) were electrophoresed on reducing 10% SDSpolyacrylamide gels. The separated proteins were transferred to PVDF membranes and probed with antibody O-17 (Assay Designs Inc.) to osteopontin.
Analysis of growth rates
For the investigation of cell growth rates, each cell line was plated at 5000 cells/well in 24-well plates. Daily, five wells per group were harvested by trypsinization and the cell numbers were determined in a Coultert Z-Series Counter. At each time point, the cell numbers from the five wells of the various groups of transfectants were analysed for statistically significant differences by the Wilcoxon-Mann-Whitney test and the t-test, accepting a probability of error of less than 5%.
Analysis of osteopontin aggregation
In all, 40 ml of supernatant from vector or OPN-a or OPN-c stable transfectants were incubated at 371C for indicated time points in aggregation buffer (0.2 M NaCl, 0.05 M Tris-HCl, pH 7.6, 5 mM CaCl 2 final concentration) or at various Ca 2 þ concentrations for 16 h. The samples were resolved on reducing denaturing SDS/polyacrylamide gels and transferred to PVDF membranes followed by Western blotting.
Adhesion assay
In all, 96-well polystyrene plates were coated with the indicated amounts of GST-OPN forms or control fibronectin (50 mg/ml) in 100 ml/well at 41C overnight. The wells were washed twice with cold PBS followed by blocking with 1% BSA for 1 h at 371C. MCF-7 parental cells were used for assaying adhesion. The cells were trypsinized and treated with soybean trypsin inhibitor, then washed twice with PBS and resuspended in adhesion buffer (0.1% BSA, 1 mM sodium pyruvate, 2 mM MgCl 2 ). Cells (2 Â 10 4 cell/well) were added to the above 96-well plates and allowed to adhere at 371C for 2 h. Nonadherent cells were removed by rinsing twice with PBS. Adherent cells were counted and photographed. For adhesion to aggregated osteopontin, GST or GST-OPN forms were added to 96-well plates in aggregation buffer (0.2 M NaCl, 0.05 M Tris-HCl, pH 7.6, 5 mM CaCl 2 final concentration) and incubated at 41C overnight. All adhesion assays were performed with triplicate wells and were repeated at least three times.
Soft agar growth
In all, 1 Â 10 5 cells per 60-mm dish were plated in triplicates with a top layer of 0.3% agar (BACTO Agar, Difco, Detroit, MI, USA) and a bottom layer of 0.5% agar (both in a-MEM). Every other day, 0.4 ml of medium was supplemented and the plates were examined microscopically for growth. After 1 week, photographs were taken at high and low magnification and the surface area of all clones in five fields was measured with the imaging software ImageJ (NIH) or Metamorph. The osteopontin expression levels on the day of plating were confirmed by Western blotting.
Microarray analysis MCF-7 transfectants were plated in soft agar, following the confirmation of their osteopontin expression by Western blotting. After 7 days of soft agar growth, the clone sizes were measured and RNA was extracted with 2 ml TriReagent LS. Linear amplification was performed with the Amino Allyl Message Amp II kit from Ambion, and the samples were subjected to microarray analysis comparing MCF-7 OPNc, MCF-7 OPNa, and MCF-7 vector. For each comparison, several hybridizations (four for OPNc versus OPNa and two each for OPNa versus vector and OPNc versus vector) were performed with RNA from distinct soft agar plates and dyeflip of the fluorescent labels. The microarray experiment was carried out as described (Hosack et al., 2003; Karyala et al., 2003; Guo et al., 2004 ) (see also http://microarray.uc.edu). The human 70-mer oligonucleotide library version 2.0 (21 329 optimized oligos) (Qiagen, Alameda, CA, USA) were printed on aminosilane-coated slides (Cel Associates Inc., Pearland, TX, USA). Fluorescence-labeled cDNAs (Cy3 and Cy5; Amersham, Piscataway, NJ, USA) for hybridization were synthesized from linearly amplified total RNA using an indirect amino allyl labeling method via an oligo(dT)-primed, reverse transcriptase reaction. The data representing background-subtracted spot intensities were analysed after log transformation and data centering.
Statistical significance of differential expression was assessed according to P-values, and adjusting for multiple hypotheses testing by calculating false discovery rates (FDR) Benjamini and Hochberg, 1995) . Estimates of foldchange were calculated, and the cutoff used for significance was a fold change of >2, an intensity of >100, and an FDR o0.05. Significantly changed transcripts were tested against functional assignments, to determine which gene categories were enriched with differentially expressed genes. This was performed with Expression Analysis Systematic Explorer (EASE), using the gene categories of the Molecular Function and Biological Process branches of the Gene Ontology database (Hosack et al., 2003) . Gene Ontology is a multiorganism, controlled vocabulary database containing three separate ontologies: biological process, molecular function, and cellular component. It is commonly used for assessing the results of microarray analyses. Fisher's Exact Probability, using the Benjamini FDR adjustment, was calculated for each gene category (Reiner et al., 2003) .
The microarray results were validated by real-time PCR, which was conducted using a Cepheid Smart Cycler and a SYBR Green detection format. Oligo-dT primed first strand cDNA was synthesized using Invitrogen SuperScript according to the manufacturer's protocol. The PCR reaction contained 0.5 Â SYBR Green (Roche Diagnostics), MgCl 2 and primer concentration were optimized for each gene. A 40 cycles PCR protocol consisted of 941C melting for 15 s, specific annealing for 30 s, and 20 s extension at 721C. Melt curves yielded a single peak in all cases with no primer dimers. A no-template control was included in all reactions. The levels of 18S rRNA were used to normalize for equal amounts of RNA.
